BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/13/2025 1:39:37 PM | Browse: 20 | Download: 156
 |
Received |
|
2025-03-05 11:30 |
|
Peer-Review Started |
|
2025-03-05 11:30 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-03-21 07:28 |
|
Revised |
|
2025-04-09 08:12 |
|
Second Decision |
|
2025-04-23 02:39 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-04-23 06:25 |
|
Articles in Press |
|
2025-04-23 06:25 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2025-04-29 03:53 |
|
Typeset the Manuscript |
|
2025-06-02 13:43 |
|
Publish the Manuscript Online |
|
2025-06-13 13:39 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Immune checkpoint inhibitors in the first-line treatment of esophageal squamous cell carcinoma: Minireview for a big shift
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Giulia Massaro, Alexandra Paulet, Daniele Lavacchi, Marco Brugia, Daniele Rossini, Elisa Giommoni, Martina Catalano, Serena Pillozzi, Lorenzo Antonuzzo and Giandomenico Roviello |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Giandomenico Roviello, Associate Professor, MD, PhD, Department of Health Sciences, University of Florence, Viale Pieraccini, Florence 50134, Tuscany, Italy. giandomenico.roviello@unifi.it |
| Key Words |
Esophageal squamous cell carcinoma; Immunotherapy; Immune checkpoint inhibitors; Programmed death ligand 1; First-line treatment |
| Core Tip |
This paper examines the evolving landscape of first-line treatments for esophageal squamous cell carcinoma, highlighting the transformative impact of immune checkpoint inhibitors. While immune checkpoint inhibitors combined with chemotherapy have improved survival, response rates remain inconsistent due to variability in programmed death ligand 1 testing and immune microenvironment changes. We critically analyze landmark phase 3 trials (KEYNOTE-590, CheckMate 648) and discuss the limitations of current biomarkers. Addressing the urgent need for more precise patient selection and novel therapeutic strategies, this review provides insights into emerging approaches that could enhance long-term survival in esophageal squamous cell carcinoma. |
| Publish Date |
2025-06-13 13:39 |
| Citation |
<p>Massaro G, Paulet A, Lavacchi D, Brugia M, Rossini D, Giommoni E, Catalano M, Pillozzi S, Antonuzzo L, Roviello G. Immune checkpoint inhibitors in the first-line treatment of esophageal squamous cell carcinoma: Minireview for a big shift. <i>World J Gastrointest Oncol</i> 2025; 17(6): 106707</p> |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i6/106707.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i6.106707 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
